Skip to main content
Caplight Logo









Iantrek

Iantrek

Private
White Plains, New YorkHealthcare & Life Scienceshttps://iantrekmed.com/

Last Round

Debt

Apr 28, 2026

Est. Valuation

$95M

Total Funding Raised

$100.22M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Iantrek is an ophthalmic medical technology company that develops micro- and bio-interventional solutions for the surgical treatment of chronic eye diseases, with a primary focus on glaucoma.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

glaucoma managementophthalmic devicesbio-interventionalminimally invasive glaucoma surgeryMIGSmedical deviceophthalmologyaqueous humor outflowintraocular pressureambulatory surgery centerASCsurgical implantglaucoma surgery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Iantrek Comparables

Compare Iantrek with similar companies based on industry and business-model similarity.

Iantrek comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avisi Technologies Inc.
85%
Myra Vision
84%
Sight Sciences
83%

Iantrek Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtApr 28, 2026
Series CAug 20, 2025
Series BAug 30, 2022
Series A ExtensionOct 22, 2020

Key People

Founding team and executive leadership

Sean Ianchulev

Founder, Chairman Of The Board, CEO

Founding Team

Mike H.

Chief Financial Officer

Executive Team

Iantrek Investors

Notable investors and investment history

Iantrek investors
InvestorRounds
U.S. Venture PartnersSeries C
aMoonSeries C
Trinity CapitalDebt
SectoralSeries C, Series B
Visionary VenturesSeries C, Series B
Civilization VenturesSeries C
JSD CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 28, 2026

    $30M round led by Trinity Capital.

  • Mar 31, 2026

    Introducing AlloSpan Canal, a bio-reinforced platform for ophthalmic surgery.

Iantrek Filings

Explore SEC and related filing metadata, where available.

Iantrek filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Iantrek's valuation, stock price, and market status.

Is Iantrek a public or private company?

Iantrek is a private company.

What is the current stock price of Iantrek?

Iantrek is a private company with no public stock price. No recent secondary market data is available.

How much is Iantrek worth (valuation)?

Valuation information for Iantrek is not publicly available.

Can I buy Iantrek stock?

Iantrek shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Iantrek's last funding round?

Iantrek's most recent funding round was Growth Equity on April 28, 2026.

Who are the main investors in Iantrek?

Key investors in Iantrek include U.S. Venture Partners, Trinity Capital.

Will Iantrek IPO soon?

No public IPO plans have been announced for Iantrek.

How can I track Iantrek secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Iantrek's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWhite Plains, New York
Employee Range70
Year Founded2019
Last FundingApr 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?